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Endovascular Aortic Repair
Versus Open Surgical Repair
for Descending Thoracic Aortic Disease
A Systematic Review and Meta-Analysis of Comparative Studies
Davy Cheng, MD,* Janet Martin, PHARMD, MSC (HTA&M),* Hani Shennib, MBBS,†
Joel Dunning, PHD,‡ Claudio Muneretto, MD,§ Stephan Schueler, PHD, MD,
Ludwig Von Segesser, MD,¶ Paul Sergeant, MD, PHD,# Marko Turina, MD**
London, Ontario, Canada; Phoenix, Arizona; Middlesbrough and Newcastle upon Tyne, United Kingdom;
Brescia, Italy; Lausanne and Zurich, Switzerland; and Leuven, Belgium
Objectives The purpose of this study was to determine whether thoracic endovascular aortic repair (TEVAR) reduces death
and morbidity compared with open surgical repair for descending thoracic aortic disease.
Background The role of TEVAR versus open surgery remains unclear. Metaregression can be used to maximally inform adop-
tion of new technologies by utilizing evidence from existing trials.
Methods Data from comparative studies of TEVAR versus open repair of the descending aorta were combined through meta-
analysis. Metaregression was performed to account for baseline risk factor imbalances, study design, and thoracic
pathology. Due to significant heterogeneity, registry data were analyzed separately from comparative studies.
Results Forty-two nonrandomized studies involving 5,888 patients were included (38 comparative studies, 4 registries). Pa-
tient characteristics were balanced except for age, as TEVAR patients were usually older than open surgery patients
(p  0.001). Registry data suggested overall perioperative complications were reduced. In comparative studies, all-
cause mortality at 30 days (odds ratio [OR]: 0.44, 95% confidence interval [CI]: 0.33 to 0.59) and paraplegia (OR:
0.42, 95% CI: 0.28 to 0.63) were reduced for TEVAR versus open surgery. In addition, cardiac complications, transfu-
sions, reoperation for bleeding, renal dysfunction, pneumonia, and length of stay were reduced. There was no signifi-
cant difference in stroke, myocardial infarction, aortic reintervention, and mortality beyond 1 year. Metaregression to
adjust for age imbalance, study design, and pathology did not materially change the results.
Conclusions Current data from nonrandomized studies suggest that TEVAR may reduce early death, paraplegia, renal insuffi-
ciency, transfusions, reoperation for bleeding, cardiac complications, pneumonia, and length of stay compared
with open surgery. Sustained benefits on survival have not been proven. (J Am Coll Cardiol 2010;55:986–1001)
© 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.047r
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oince the introduction of thoracic endovascular aortic
epair (TEVAR) using stent grafts for complicated dis-
ases of the descending thoracic aorta, there has been
ebate regarding the safety, efficacy, and durability of this
pproach. Until recently, options for the management of
horacic aortic disease were limited to open surgical
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witzerland; #Cardiac Surgery Department, Gasthuisberg University Hospital, 1epair or conservative medical management. After the
rst formal publication of a case series describing the
utcome of 13 patients undergoing TEVAR for descend-
ng thoracic aneurysm in the early 1990s (1), the subse-
uent pace of uptake of TEVAR has outstripped ade-
uate evaluation of the evidence for its benefits and risks.
euven, Belgium; and **Cardiac Surgery, University Hospital Zurich, Zurich,
witzerland. Support for the meta-analysis was provided by an unrestricted research
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March 9, 2010:986–1001 TEVAR Versus Open Surgical Repair of the Descending Aortao date, no randomized trials of TEVAR versus open
urgical repair for descending thoracic aortic disease have
een performed. Most published reports describing
EVAR consist of uncontrolled retrospective cohorts or
ase series. Recently, a number of nonrandomized phase II
tudies have compared endovascular repair with a concur-
ent or historical open surgical group. In the absence of
efinitive randomized controlled trials, the value of TEVAR
elative to conventional open surgical approaches will con-
inue to be debated (2–4).
When randomized trials are unavailable, metaregres-
ion can be performed to maximize the knowledge gained
rom existing comparative studies in order to optimally
irect future patient care decisions and need for further
esearch. A methodologically rigorous meta-analysis with
etaregression to account for baseline demographics is
rgently needed to clarify the overall benefit-to-risk ratio
f TEVAR versus open surgical repair for complicated
iseases of the descending thoracic aorta, and to better
nform further research in this area. Metaregression may
lso shed light on the balance of outcomes across various
atient subgroups with differing pathologies of the aorta.
isease of the descending thoracic aorta requiring surgi-
al or endovascular intervention may include degenerative
neurysm, dissection, traumatic rupture, intramural he-
atoma, and penetrating aortic ulcer. Previous meta-
nalyses of TEVAR assessed only noncomparative stud-
es (5), did not include more recent studies (5–7), focused
nly on 1 pathology such as blunt injury (6 –10), or
electively reported only 1 outcome such as death (10).
his study was commissioned by the European Associa-
ion of Cardiothoracic Surgery to address the current
vidence for adoption of TEVAR. The objective was to
erform a comprehensive meta-analysis with metaregression of
vailable comparative studies to determine whether TEVAR
mproves morbidity, mortality, and resource-related outcomes
Citations Screened:
2894
(up to March 2009) 
Full-text articles retrieved: 
543
Relevant nRCT trials: 
4 multicenter (973)
35 single center (1855)
3 registries (3060)
= 42 studies (5,888 patients) 
Figure 1 Results of Literature Search
The flow chart outlines the total number of potentially relevant citations reviewed a
screening. Reasons for inclusion and exclusion are outlined. CoA  coarctation; nompared with open surgery for
dults presenting with thoracic
ortic disease.
ethods
his analysis was planned in
ccordance with current guide-
ines for performing compre-
ensive systematic reviews and
eta-analyses with regression, including the PRISMA
Preferred Reporting Items for Systematic reviews Meta-
nalyses) (11) and MOOSE (Meta-analysis Of Obser-
ational Studies in Epidemiology) (12) guidelines for
andomized and nonrandomized studies, respectively. A
rotocol pre-specified outcomes, search strategies, inclu-
ion criteria, and statistical analyses.
earch strategy. A search was performed by biblio-
raphic experts to identify all studies in MEDLINE,
ochrane Central Register of Controlled Trials on The
ochrane Library, International Association of Health
echnology Assessment (INAHTA), and EMBASE
rom 1990 to March 2009, as well as surgical meeting
bstracts from 2006 to 2009. The Food and Drug
dministration devices database was also accessed for
dditional unpublished data. Search terms included com-
inations and derivatives of the following as textwords
nd MESH terms: (thorac* AND aort*) OR aneurys* OR
issect* OR “penetrating atherosclerotic ulcer” OR “in-
ramural hemorrhage” OR trauma* OR rupture*) AND
endovasc* OR endostent* OR surg* OR operat* OR
EVAR OR EVAR OR stent*). After the initial
earches were completed and potentially relevant studies
dentified, additional tangential searches were conducted
sing related article links within MEDLINE. In addi-
ion, individual searches for specific names of commercial
tents were performed to identify further TEVAR stud-
Non-relevant Trials Excluded before 
Retrieval:
2351
on-relevant Trials Excluded after 
etrieval: 491
Medical Comparison (no OPEN) 
“Open stenting” 
Hybrid or Elephant trunk 
Marfan, CoA, Mycotic, Type IV, Type A 
No relevant outcomes 
llected for full-text
nonrandomized controlled trial.
Abbreviations
and Acronyms
CI  confidence interval
OR  odds ratio
TEVAR  thoracic
endovascular aortic repair
WMD  weighted mean
differenceN
R
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TEVAR Versus Open Surgical Repair of the Descending Aorta March 9, 2010:986–1001es, including Gore TAG (Gore, Flagstaff, Arizona),
xcluder (Gore), AneuRx (Medtronic, Sunnyvale, Cali-
ornia), Talent (World Medical Manufacturing, Sunrise,
lorida), Vanguard (Boston Scientific, Natick, Massa-
husetts), Zenith (Cook, Indianapolis, Indiana), Stentor
haracteristics of Included Comparative Studies for TEVAR VersusTable 1 Characteristics of Included Comparative Studies for TE
Authors, Year
(Study) (Ref. #) n Pathology
Type of
Control
Multicenter studies
Bavaria/Makaroun (GORE TAG) (23–30) 234 Aneurysm Overlapping U
Demetriades et al., 2008 (AAST) (35) 125 Trauma Concomitant U
Matsumura et al., 2008 (TX2) (51–54) 230 Mixed Overlapping U
Fairman et al., 2008 (VALOR) (42,43) 384 Mixed Concomitant U
Single-center studies
Aasland et al., 2005 (19) 60 Mixed Historic E
Akowuah et al., 2007 (20) 15 Trauma Concomitant E
Amabile et al., 2004 (21) 20 Trauma Historic E
Andrassy et al., 2006 (22) 46 Trauma Historic E
Brandt et al., 2004 (31) 44 Mixed Concomitant E
Broux et al., 2006 (32) 30 Trauma Concomitant E
Buz et al., 2008 (33) 74 Trauma Overlapping E
Chung et al., 2008 (34) 103 Trauma Historic C
Cook et al., 2006 (36) 42 Trauma Concomitant U
Dick et al., 2008 (37) 136 Mixed Concomitant E
Doss et al., 2005 (38,39) 54 Rupture Concomitant E
Ehrlich et al., 1998 (40,41) 68 Aneurysm Overlapping E
Geisbusch et al., 2009 (45) 28 Trauma Overlapping E
Glade et al., 2005 (44) 95 Aneurysm Historic E
Kasirajan et al., 2003 (46) 27 Trauma Concomitant U
Keiffer et al., 2009 (47) 163 Aneurysm Concomitant E
Kokotsakis et al., 2007 (48) 32 Trauma Concomitant E
Kuhne et al., 2005 (49) 42 Trauma Concomitant E
Lebl et al., 2006 (50) 17 Trauma Historic U
McPhee et al., 2007 (55) 27 Trauma Concomitant U
Midgely et al., 2007 (56) 28 Trauma Overlapping C
Moainie et al., 2008 (57) 52 Trauma Historic U
Mohan et al., 2008 (58) 26 Trauma Concomitant A
Morishita et al., 2004 (59,61) 29 Rupture Concomitant A
Najibi et al., 2002 (60) 34 Aneurysm Historic U
Nienaber et al., 2003 (63) 22 Dissection Historic E
Nienaber et al., 1999 (62) 24 Dissection Concomitant E
Ott et al., 2004 (64) 18 Trauma Historic C
Pacini et al., 2005 (65) 69 Trauma Overlapping E
Patel et al., 2008 (66,67) 93 Mixed Overlapping U
Reed et al., 2006 (68) 24 Trauma Overlapping U
Riesenman et al., 2007 (69) 62 Trauma Overlapping U
Rousseau et al., 2005 (70) 64 Trauma Historic E
Stampfl et al., 2006 (71) 10 Trauma Historic E
Stone et al., 2006/Conrad et al., 2008
(72,76)
173 Mixed Overlapping U
Yamane et al., 2008 (77) 26 Trauma Overlapping U
Orandi et al., 2009 (AHRQ) (74) 1,030 Mixed Concomitant U
Reuben et al., 2007 (NTDB) (75) 1,788 Trauma Concomitant U
Tsai et al., 2006 (IRAD) (73) 242 Dissection Concomitant E
Mixed  a variety of stents used; Homemade  custom-created stent described as homemade
AAST  American Association for the Surgery of Trauma; IRAD  International Registry of Acute Aorti
VE Talent Thoracic Stent Graft System for the Treatment of Thoracic Aneurysms.MinTec, La Ciotat, France), Relay (Bolton Medical,
arcelona, Spain), Endofit (Endomed, Inc., Phoenix,
rizona), E-Vita (Jotec, Heitchingen, Germany), and
X1 or TX2 (Cook). Reference lists of relevant studies
nd recent overviews were also reviewed for additional
SurgeryVersus OPEN Surgery
ocation Year Stent Name*
1998–2001 Gore
tralia, Europe 2006 Mixed (Gore Tag, Talent, Vanguard, Zenith)
ada 2004–2006 Zenith Cook
2003–2005 Talent
1985–2003 Unspecified
2000–2006 Talent
1998–2004 Talent or Gore
1997–2005 Mixed (Talent, Excluder, Zenith)
1995–2003 Talent
1995–2005 Mixed (Talent, Thoracic Excluder)
1987–2007 Mixed (Talent [n 27], e-Vita [n  9], Relay [n  3])
1995–2003 Mixed (Talent, Zenith)
2000–2005 Mixed
2001–2005 Mixed
1999–2002 Talent or Gore
1989–1997 Talent
1990–2007 Gore Tag, Talent/Valiant
1997–2003 Mixed
1999–2002 Mixed (Talent [n  3], Thoracic Excluder [n  1],
homemade graft [n  1])
1997–2005 Unspecified
2002–2006 Mixed (Talent, Valiant, Relay)
1998–2002 Mixed
1997–2003 Mixed
2000–2004 Mixed (Talent, Thoracic Excluder)
1994–2006 Talent
2005–2007 Gore
2000–2007 Mixed
2001–2004 Homemade
1996–2005 Talent or Gore
1998–2002 Talent
1997–1998 Talent
1991–2002 Talent
1980–2003 Mixed (Talent, Gore Excluder)
1993–2007 Mixed
2000–2005 Mixed (Aneurx or Excluder)
1993–2006 Mixed (Gore TAG, Talent, Vanguard, Excluder
extension cuffs)
1981–2003 Mixed (Talent, Thoracic Excluder, Vanguard)
1993–2004 Mixed (Talent or Gore)
1996–2005 Mixed
1999–2007 Mixed
2005–2005 Mixed
1994–2003 Mixed
Canada, U.S. 1996–2003 Mixed
uthors.OPENVAR
L
.S.
.S., Aus
.S., Can
.S.
urope
urope
urope
urope
urope
urope
urope
anada
.S.
urope
urope
urope
urope
urope
.S.
urope
urope
urope
.S.
.S.
anada
.S.
ustralia
sia
.S.
urope
urope
anada
urope
.S.
.S.
.S.
urope
urope
.S.
.S.
.S.
.S.
urope,
by the a
c Dissection; TEVAR  thoracic endovascular aortic repair; VALOR  Evaluation of the Medtronic
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March 9, 2010:986–1001 TEVAR Versus Open Surgical Repair of the Descending Aortatudies. Studies in any language, whether published or
npublished, were eligible for inclusion. Selected authors
f clinical studies and experts were contacted to further
dentify unpublished studies of TEVAR versus open
urgery management.
tudy retrieval and selection criteria. Trials identified as
otentially relevant on the basis of title or abstract were
elected for full review. Two reviewers independently
ssessed these trials for eligibility based on prespecified
nclusion criteria. Disagreement was resolved by consen-
us with third party adjudication.
For the primary analysis, all studies comparing TEVAR
ith open surgery were eligible if they enrolled at least 10
dults with descending thoracic aneurysm disease and re-
orted at least 1 clinically relevant or resource-related
utcome. Eligible aortic pathologies included thoracic aortic
neurysm, dissection, rupture, trauma, penetrating aortic
lcer, or intramural hemorrhage, whether chronic or acute,
mergent or elective. Studies of coarctation or Marfan
yndrome, hybrid procedures, Type A aneurysm, and com-
ined thoracic and abdominal aortic disease were excluded.
f studies provided outcomes across a number of thoracic
orta pathologies, only the relevant subgroups were
ncluded.
ata extraction and outcomes definitions. Two review-
rs independently assessed studies for inclusion criteria,
nd data were extracted independently by the lead re-
iewer and at least 1 additional reviewer. Discrepancies
ere resolved by consensus with international authors at
esignated consensus meetings. Data were extracted onto
tandard forms, and included baseline demographics,
ortic pathology, duration of follow-up study sites, study
esign, years of enrollment, whether patients were con-
ecutively enrolled, and loss to follow-up. Studies from
enters that included the same set of patients over
ifferent time frames were carefully evaluated to include
nly updated follow-up data.
For clinical outcomes, definitions provided by authors
f the studies were generally used as provided. Death was
efined as cumulative incidence of all-cause mortality.
ncidence of paraplegia or paraparesis, whether perma-
ent or temporary, was reported as an aggregate outcome,
nd only post-operative incidence of new paraplegia or
araparesis was considered (i.e., preprocedural paraplegia
ue to trauma was not considered relevant). Permanent
araplegia was defined as paraplegia persisting at the time
f last study follow-up. Renal dysfunction was defined as
er the authors’ definition (increases in serum creatinine
ver baseline by more than 50% or need for renal
eplacement therapy). Incidence of transfusions was de-
ned as the cumulative number of patients transfused
lood products post-operatively. The composite outcome
f any cardiac complications was recorded only when the
tudy authors provided the number of patients experienc-
ng any complication related to cardiovascular system
ost-operatively, typically defined as 1 or more episodes tf ischemia, infarction, hemodynamic instability, low
ardiac output syndrome, or arrhythmia. Endoleaks were
lassified according to the usual nomenclature (13). Early
ndoleak was defined as occurring within 30 days, and
ate endoleak as occurring or persisting at follow-up
eyond 30 days.
tatistical analysis. Planned subanalyses included analy-
is by study design (single-center series, multicenter
tudies, and registries; unfortunately, randomized studies
ere unavailable), aortic pathology (degenerative aneu-
ysm, dissection, trauma, rupture, and intramural hem-
rrhage/penetrating aortic ulcer), and by type of stent
commercial and noncommercial or homemade).
Potential confounding due to selection bias or differ-
ntial intensity of follow-up in the observational studies
as evaluated by measuring whether there were impor-
ant differences between TEVAR and open surgical
roups in baseline patient characteristics or study design
haracteristics including age, sex, aortic pathology, ur-
ency of intervention, and comorbidities including smok-
ng history, chronic obstructive pulmonary disease, dia-
etes, hypertension, coronary artery disease, and length
f follow-up. Metaregression was performed to measure
he impact of baseline characteristics and pathologies on
he effect size for death, stroke, or paraplegia. To
etermine the impact of time and the learning curve,
etaregression was also performed by year of patient
nrollment defined for each study as the median year
ithin the range of years during which patient data were
ollected. When date ranges for patient enrollment were
ot provided, the year was assumed to be 3 years prior to
he date of publication. Sensitivity analysis was planned
or the following indicators of study quality: prospective
ersus retrospective data collection, consecutive patient
ecruitment versus nonconsecutive patient inclusion, and
istoric versus concomitant control groups.
In evaluating multiple publications of overlapping
atient populations, we classified all studies by the
enter(s) and dates of patient enrollment, and selected
he most recent and/or most complete series from each
enter to extract as many relevant outcomes as possible.
hen the more recent series failed to report all outcomes
aseline Characteristics for Included PatientsTable 2 Baseline Characteristics for Included Patients
TEVAR Open Surgery p Value
Male 61.9 67.0 0.84
CAD 41.9 36.2 0.31
Diabetes 13.8 9.1 0.23
COPD 38.1 32.3 0.13
Smoker 76.0 71.1 0.21
Hypertension 79.6 78.3 0.84
Renal insufficiency 9.9 13.6 0.74
Age, yrs 54 13 51 13 0.001
alues are % or mean  SD.
CAD  coronary artery disease; COPD  chronic obstructive pulmonary disease; TEVAR 
horacic endovascular aortic repair.
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TEVAR Versus Open Surgical Repair of the Descending Aorta March 9, 2010:986–1001linical Outcomes for MC, SC, and All StudiesTable 3 Clinical Outcomes for MC, SC, and All Studies
Design n/N TEVAR, %* n/N Open Surgery, %* I2, % OR (95% CI) p Value
Death, 30-day
MC 18/676 41/421 0 0.24 (0.13–0.44) 0.00001
SC 62/773 165/1,008 0 0.53 (0.38–0.74) 0.0001
All 80/1,444 5.8 206/1,429 13.9 0 0.44 (0.33–0.59) 0.00001
Death, 1-yr
MC 44/352 49/259 0 0.68 (0.43–1.06) 0.09
SC 55/260 61/249 7 0.81 (0.49–1.32) 0.39
All 99/612 16.0 110/508 21.9 0 0.73 (0.53–1.02) 0.07
Death, 2- to 3-yr
MC 36/140 26/94 0 0.91 (0.50–1.63) 0.74
SC 42/194 45/195 0 0.93 (0.63–1.33) 0.65
All 78/334 23.0 71/289 24.8 0 0.92 (0.63–1.33) 0.65
Paraplegia, paraparesis
MC 31/620 48/411 28 0.44 (0.23–0.84) 0.01
SC 15/769 75/1,063 0 0.40 (0.24–0.68) 0.001
All 46/1,389 3.4 123/1,474 8.2 0 0.42 (0.28–0.63) 0.0001
Permanent paraplegia
MC 7/495 16/343 0 0.29 (0.12–0.71) 0.007
SC 2/215 15/282 0 0.31 (0.09–1.11) 0.07
All 9/710 1.4 31/625 4.9 0 0.30 (0.14–0.62) 0.001
Stroke
MC 19/495 27/343 0 0.46 (0.25–0.85) 0.01
SC 34/539 35/669 10 1.12 (0.64–1.94) 0.70
All 53/1,034 5.0 62/1,012 6.2 23 0.75 (0.50–1.13) 0.17
AMI
MC 3/495 11/343 0 0.26 (0.08–0.86) 0.03
SC 13/208 33/358 0 1.25 (0.59–2.66) 0.56
All 16/703 2.3 44/701 6.3 20 0.81 (0.43–1.53) 0.51
Renal dysfunction
MC 39/615 76/410 66 0.36 (0.16–0.82) 0.01
SC 19/390 69/536 0 0.42 (0.24–0.72) 0.0001
All 58/1,005 5.9 145/946 15.7 0 0.40 (0.25–0.63) 0.001
Ischemia, limb or gut
MC 7/530 7/452 0 0.75 (0.25–2.70) 0.60
SC 5/117 3/130 13 1.29 (0.32–5.29) 0.72
All 12/647 1.9 10/582 1.7 0 0.92 (0.39–2.21) 0.86
Reoperation for bleeding
MC 0/160 3/70 0 0.06 (0.003–1.18) 0.06
SC 4/304 27/392 0 0.30 (0.12–0.74) 0.009
All 4/464 0.01 30/462 6.5 0 0.26 (0.11–0.62) 0.002
Transfused patients
MC 5/160 61/70 0 0.005 (0.002–0.015) 0.0001
SC 2/17 16/22 0 0.04 (0.004–0.34) 0.004
All 7/177 3.9 77/92 83.7 23 0.01 (0.002–0.04) 0.0001
Reintervention
MC 13/298 4/164 57% 1.89 (0.18–19.0) 0.60
SC 40/389 44/413 0% 0.99 (0.62–1.58) 0.97
All 53/687 8.1 48/577 9.1 0% 1.01 (0.64–1.60) 0.95
Pneumonia
MC 57/319 64/246 73 0.54 (0.23–1.23) 0.14
SC 15/134 66/207 22 0.32 (0.15–0.69) 0.003
All 72/453 15.9 130/453 28.7 44 0.14 (0.23–0.71) 0.002
Wound infections
MC 20/300 18/164 0 0.70 (0.20–2.47) 0.58
SC 1/66 8/82 0 0.19 (0.03–1.11) 0.07
All 21/366 5.7 26/246 10.6 0 0.42 (0.16–1.27) 0.13Continued on next page
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March 9, 2010:986–1001 TEVAR Versus Open Surgical Repair of the Descending Aortaf interest, we referred to the next most current series
rom the same center, and extracted the remaining
utcomes as far as possible. When it became apparent
hat a number of single-center experiences were pub-
ished with overlapping patient datasets as those included
n multicenter phase II trials or registries, we decided to
resent the data aggregated by each study type (consec-
tive series, multicenter trial, and registries), and to
ombine the results across multicenter and single-center
tudies only when the degree of overlap was likely to be
ow, if any. Registry data were not aggregated together
ith multicenter and single-center studies, since the
egree of overlap was likely to be large, and since
ignificant heterogeneity was detected between the reg-
stry aggregate data compared with nonregistry data.
Patient characteristics and outcomes were entered into
database, and analysed using Comprehensive Meta-
nalysis Software version 2 (Biostat, Littlewood, New
ersey). For dichotomous variables, individual and pooled
tatistics were calculated as weighted odds ratios (ORs)
ith 95% confidence intervals (CIs). For continuous
utcomes, individual and pooled statistics were calculated
s weighted mean differences (WMD) and 95% CIs.
ince heterogeneity was anticipated across the trials, the
andom effects model was used for all calculations to
rovide an overall conservative analysis (14). For the
rimary analysis, data were combined within each cate-
ontinuedTable 3 Continued
Design n/N TEVAR, %* n/N
Ischemia, limb or gut
MC 5/335 6/273
SC 5/117 3/130
All 10/452 2.2 9/403
Neurologic complications
MC 54/495 81/343
SC 2/140 22/207
All 56/635 8.9 103/550
Cardiac complications
MC 78/495 139/343
SC 6/67 27/172
All 84/562 14.6 166/515
Respiratory complications
MC 57/690 164/522
SC 39/213 120/338
All 96/903 11.1 284/860
Vascular complications
MC 89/690 112/522
SC 1/8 0/5
All 90/698 13.0 112/527
Overall complications
MC 240/620 295/411
SC 24/143 82/179
All 264/763 41.4 379/590
Incidence of events using weighted events across studies.
All  all studies combined; AMI  acute myocardial infarction; CI  confidence interval; MC ory of study type (single-center series, multicenter trials, segistries), and presented by study subtype and in aggre-
ate (for single-center and multicenter data only). For
ubanalyses by pathology, by study design, and by type of
tent used, data were combined across subgroups using
he mixed effects analysis. The test for interaction was
mployed to determine whether effect sizes differed
ignificantly across subgroups. We preferentially captured
ntention-to-treat data whenever available (15).
Heterogeneity across trials was explored for each outcome
y calculating I2, which indicates the percent of heteroge-
eity across trials that cannot be explained by chance
ariation alone (16,17). I2 50% was considered to indicate
igh heterogeneity. Publication bias was assessed through
unnel plots, and Egger’s regression test was applied (18).
esults
n total, 2,894 abstracts were identified for screening, and
total of 42 studies reported in 59 papers involving
,888 patients met the inclusion criteria for this analysis
19 –77). Fifteen papers described 4 multicenter observa-
ional trials (23–30,35,42,43,51–54), 3 papers described
registries (73–75), and the remainder of papers de-
cribed cohorts or series of patients undergoing TEVAR
ersus concurrent or historical control groups, from single
enters. Figure 1 outlines the results of the search
Open Surgery, %* I2, % OR (95% CI) p Value
14 0.62 (0.15–2.52) 0.51
12 1.29 (0.32–5.29) 0.72
2.4 8 0.89 (0.33–2.41) 0.83
41 0.41 (0.24–0.68) 0.001
0 0.22 (0.07–0.74) 0.01
18.7 5 0.37 (0.23–0.59) 0.0001
0 0.29 (0.14–0.62) 0.001
0 0.51 (0.21–1.28) 0.15
32.1 0 0.37 (0.20–0.66) 0.001
0 0.21 (0.15–0.29) 0.0001
39 0.50 (0.26–0.96) 0.04
33.2 48 0.25 (0.18–0.33) 0.0001
87 0.50 (0.15–1.60) 0.24
0 2.20 (0.08–6.49) 0.65
21.9 83 0.58 (0.19–1.76) 0.34
88 0.16 (0.06–0.41) 0.0001
15 0.23 (0.10–0.53) 0.001
69.3 63 0.19 (0.10–0.36) 0.0001
enter; OR  odds ratio; SC  single-center; TEVAR  thoracic endovascular aortic repair.trategy, and Table 1 describes the included studies.
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TEVAR Versus Open Surgical Repair of the Descending Aorta March 9, 2010:986–1001Weighted analysis across all studies showed that baseline
haracteristics were similar between TEVAR and open groups
or the following: sex, hypertension, coronary artery disease,
hronic obstructive pulmonary disease, and smoking status
Table 2). However, patients included in the TEVAR group
ere older on average by nearly 3 years than patients included
n the open surgery group, and this difference was statistically
ignificant (age 54  13 years for TEVAR versus 51  13
ears for open surgery; p  0.001), underscoring the need for
etaregression analysis to assess the impact of age differences
t baseline on outcomes estimates for TEVAR versus open
urgery.
linical outcomes. Clinical outcomes are summarized in
able 3, subanalyzed by study category.
perative death and all-cause mortality. Cumulative 30-
ay all-cause mortality was reduced for TEVAR versus open
urgery (OR: 0.44, 95% CI: 0.33 to 0.59). Cumulative all-
Study name Statistics for each study
Odds Lower Upper 
ratio limit limit p-Value
Demetriades 08 0.25 0.10 0.61 0.00
Fairman 08 0.24 0.08 0.75 0.01
Matsumura 08 0.32 0.07 1.45 0.14
TAG 99-01/03-03 0.16 0.03 0.78 0.02
0.24 0.13 0.44 0.00
Aasland 05 0.25 0.03 2.29 0.22
Akowuah 07 0.33 0.01 9.57 0.52
Amabile 04 0.37 0.01 10.18 0.56
Andrassy 06 0.58 0.09 3.82 0.57
Brandt 04 0.13 0.01 1.16 0.07
Broux 06 0.59 0.09 3.86 0.58
Buz 08 0.33 0.08 1.41 0.13
Chung 08 0.67 0.11 3.95 0.65
Cook 06 0.80 0.19 3.37 0.76
Dick 2008 0.89 0.24 3.33 0.86
Doss 05 0.15 0.02 1.36 0.09
Ehrlich 98 0.25 0.03 2.10 0.20
Geisbusch 09 0.30 0.05 1.91 0.20
Glade 05 0.39 0.07 2.05 0.27
Kasirajan 03 0.25 0.02 3.10 0.28
Keiffer 08 3.48 1.14 10.62 0.03
Kokotsakis 07 0.43 0.02 7.63 0.56
Kuhne 05 0.43 0.02 8.71 0.58
Lebl 06 0.67 0.05 9.19 0.76
McPhee 07 1.33 0.09 20.11 0.84
Midgely 07 0.08 0.00 1.69 0.11
Moainie 08 1.00 0.22 4.51 1.00
Mohan 2008 0.38 0.03 4.87 0.46
Morishita 04 2.00 0.18 22.06 0.57
Najibi 02 0.16 0.01 4.37 0.28
Nienaber 99 0.31 0.01 8.31 0.48
Ott 04 0.32 0.01 7.85 0.49
Pacini 05 0.34 0.02 6.69 0.48
Patel 08 0.30 0.07 1.23 0.09
Reed 06 3.00 0.26 33.97 0.37
Riesenman 07 0.25 0.05 1.27 0.09
Rousseau 05 0.08 0.00 1.43 0.09
Stone 06 0.47 0.19 1.17 0.10
0.53 0.38 0.74 0.00
0.44 0.33 0.59 0.00
Overall
Single center 
Multicenter 
I2 = 0% 
Figure 2 Death at 30 Days for TEVAR Versus Open Surgery
Meta-analysis comparing death at 30 days for thoracic endovascular aortic repair
plotted. A pooled estimate of overall OR (diamonds) and 95% confidence intervals
Effects to the left of 1.0 favor TEVAR; effects to the right favor open surgery. Whe
the effect is not significantly different. The I2 for heterogeneity was not significant,ause mortality at 1 year (OR: 0.73, 95% CI: 0.53 to 1.02;
2 0%) and at 2 to 3 years did not differ significantly between
EVAR and open surgery groups (OR: 0.92, 95% CI: 0.63 to
.34; I2  0%).
The reduction in all-cause mortality at 30 days was greater
n multicenter trials (OR: 0.24, 95% CI: 0.13 to 0.44) than for
ingle-center series (OR: 0.53, 95% CI: 0.38 to 0.74), and the
value for interaction across study type was significant (p 
.020). Mortality at 1 year and beyond was similar in multi-
enter and single-center studies. Figures 2 to 4 summarize the
esults for all-cause mortality at each period of follow-up.
unnel plots (not shown) did not indicate a significant risk of
ublication bias for the outcome of mortality.
troke. The overall risk of stroke was similar for TEVAR
single-center and multicenter studies combined) versus open
urgery (OR: 0.75, 95% CI: 0.50 to 1.13; I2  23%). In
ubgroup analysis, stroke was significantly reduced in multi-
Odds ratio and 95% CI
0.1 1 10
Favors TEVAR Favors OPEN
100
) versus open surgery. The odds ratio (OR) for death from each included study is
h of diamonds) summarizes the effect size using the random effects model.
horizontal bars of an individual study, or the pooled diamond width, cross 1.0,
sting homogeneity in effect size across each study.0.01
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March 9, 2010:986–1001 TEVAR Versus Open Surgical Repair of the Descending Aortaenter trials of TEVAR versus open surgery (OR: 0.46, 95%
I: 0.25 to 0.85). Subanalysis of single-center series alone
id not show significant reduction in stroke for TEVAR
ersus open surgery (OR: 1.12, 95% CI: 0.64 to 1.94).
here was significant interaction across multicenter ver-
us single-center subgroups (p  0.021) (Fig. 5).
araplegia and paraparesis. Paraplegia or paraparesis (per-
anent or temporary) was significantly reduced for TEVAR
ersus open surgery (OR: 0.42, 95% CI: 0.28 to 0.63) (Fig. 6).
ermanent paraplegia was also significantly reduced (OR:
.30, 95% CI: 0.14 to 0.62; I2  0%). The magnitude of
eduction in risk of paraplegia or paraparesis and permanent
araplegia was similar in multicenter and single-center studies
p values for interaction across studies were 0.83 and 0.92,
espectively).
ther clinical outcomes. Compared with open surgery,
EVAR significantly reduced risk of renal dysfunction
OR: 0.40, 95% CI: 0.25 to 0.63), reoperation for bleeding
OR: 0.26, 95% CI: 0.11 to 0.62), and incidence of
ransfusion (OR: 0.01, 95% CI: 0.002 to 0.04). Other
utcomes that were significantly improved with TEVAR
ncluded cardiac, pneumonia, and respiratory complications.
EVAR significantly reduced the composite outcome of
ny complication compared with open surgery (OR: 0.23,
5% CI: 0.12 to 0.44).
Hospital length of stay was significantly reduced (WMD:
7 days, 95% CI: 10 to 5 days). Similarly, total intensive
are unit length of stay was significantly reduced by 4 days (4
Study name Statistics for each stu
Odds Lower Upper 
ratio limit limit
Fairman 08 (VALOR)0.741 0.440 1.247
Matsumura 08 0.531 0.221 1.276
0.679 0.434 1.063
Amabile 04 0.368 0.013 10.178
Broux 06 0.591 0.090 3.864
Buz 2008 0.958 0.365 2.514
Dick 2008 2.143 0.756 6.074
Doss 05 0.148 0.016 1.358
Kasirajan 03 0.250 0.020 3.100
Kokotsakis 07 0.900 0.072 11.254
Najibi 02 0.438 0.070 2.728
Nienaber 99 0.076 0.004 1.594
Patel 08 0.918 0.404 2.090
0.806 0.492 1.323
0.734 0.526 1.023Overall
Single center 
Multicenter 
I2 = 0% 
Figure 3 Death at 1 Year for TEVAR Versus Open Surgery
Meta-analysis comparing death at 1 year for thoracic endovascular aortic repair (T
plotted. A pooled estimate of overall OR (diamonds) and 95% confidence intervals
Effects to the left of 1.0 favor TEVAR; effects to the right favor open surgery. Whe
the effect is not significantly different. The I2 for heterogeneity was not significant,ays, 95% CI: 5 to 3 days). Procedure time was signifi- fantly reduced by a mean of 140 min for TEVAR versus open
urgery (WMD:142 min, 95% CI:200 to87 min; I2
0%). The higher heterogeneity in length of stay and proce-
ure time was due to difference in magnitude of effect across
tudies rather than due to differences in direction of effect or
tudy design.
Clinical outcomes that did not differ between TEVAR and
pen surgery included myocardial infarction, ischemic compli-
ations (gut or limb), vascular complications, wound infections,
ortoesophageal fistula, laryngeal nerve injury, phrenic nerve
njury, post-operative dissection or rupture, and need for
eintervention. These outcomes were less commonly reported
n the trials, and power was inadequate to rule out the potential
or clinically and statistically significant differences in future
tudies. Patient-reported outcomes such as pain, functionality,
uality of life, and patient satisfaction were not reported in the
rials.
ndoleaks. The reported incidence of endoleak was
2.1% (95% CI: 13.0 to 17.4%) when limited to studies
n which endoleaks were definitively reported. However,
his may be an overestimate, since many studies did not
xpressly report endoleaks, and we did not presume that
he incidence was zero when endoleaks were not men-
ioned. Since most of the studies failed to provide
ufficient details about the endoleaks, it was not possible
o analyze the aggregate incidence of early versus late
ndoleak and the different subtypes of endoleaks. Stent
Odds ratio and 95% CI
e
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0.01 0.1 1 10 100
Favors TEVAR Favors OPEN
versus open surgery. The odds ratio (OR) for death from each included study is
h of diamonds) summarizes the effect size using the random effects model.
horizontal bars of an individual study, or the pooled diamond width, cross 1.0,
sting homogeneity in effect size across each study.dy
p-Valu
0.25
0.15
0.09
0.55
0.58
0.93
0.15
0.09
0.28
0.93
0.37
0.09
0.83
0.39
0.06
EVAR)
(widt
n the
suggeractures and migration were reported rarely.
M
b
r
o
g
s
p
o
s
b
d
s
a
d
n
p
t
(
n
s
t
s
r
n
f
p
t
a
R
i
I
f
o
a
r
r
d
a
n
i
t
a
o
a
c
D
T
o
a
s
n
d
u
i
t
994 Cheng et al. JACC Vol. 55, No. 10, 2010
TEVAR Versus Open Surgical Repair of the Descending Aorta March 9, 2010:986–1001etaregression and other subanalyses. Metaregression
y baseline age did not impact the relative reduction in
isk of death, stroke, and paraplegia for TEVAR versus
pen surgery (i.e., the results were consistent across age
roups) (Fig. 7). Similarly, when the results for death,
troke, and paraplegia were analyzed by different aortic
athologies, the relative reductions for TEVAR versus
pen surgery were similar across subgroups (data not
hown). Many comparative studies failed to report outcomes
y specific type of pathology, and of those that did, only
egenerative aneurysm and trauma were adequately repre-
ented in most subanalyses. In addition, ORs for death, stroke,
nd paraplegia did not differ by prospective versus retrospective
esign, historic versus concurrent control, consecutive versus
onconsecutive patient recruitment. Metaregression by year of
atient recruitment showed that the results were similar over
ime since the slope of effect size over time was nonsignificant
Figs. 8 to 10).
Subanalysis by commercial and homemade stent was
ot possible due to very few patients receiving homemade
tents in this analysis. Analysis of outcomes by different
ypes of commercial stents was not possible since most
tudies used a variety of commercial stents, and few
eported outcomes individually by type of stent used.
Examination of publication bias and funnel plots did
ot reveal a statistically significant risk of publication bias
or any of the clinical outcomes, including death, para-
legia, stroke, cardiac complications, and renal dysfunc-
ion. For some outcomes, the paucity of data precluded
Study name Statistics for each s
Odds Lower Upper 
ratio limit limit
TAG 99-01 0.905 0.502 1.633
0.905 0.502 1.633
Amabile 04 0.368 0.013 10.178
Broux 06 0.591 0.090 3.864
McPhee 07 0.500 0.045 5.514
Buz 08 0.846 0.325 2.200
Dick 08 1.959 0.826 4.648
Doss 05 0.679 0.183 2.525
Kokotsakis 07 0.400 0.048 3.348
Geisbusch 09 0.491 0.091 2.636
0.925 0.566 1.513
0.917 0.629 1.338
Multicenter
Single center
Overall
I2 = 0%
Figure 4 Death at 2 to 3 Years for TEVAR Versus Open Surgery
Meta-analysis comparing death at 2 to 3 years for thoracic endovascular aortic rep
study is plotted. A pooled estimate of overall OR (diamonds) and 95% confidence
model. Effects to the left of 1.0 favor TEVAR; effects to the right favor open surge
cross 1.0, the effect is not significantly different. The I2 for heterogeneity was notdequate power for robust analysis of publication bias. aegistry data. Registry data showed significant reduction
n overall complications with TEVAR versus open repair.
n contrast to comparative studies, meta-analysis of data
rom published registries that compared TEVAR with
pen surgery failed to show significant reduction in
ll-cause mortality, stroke, myocardial infarction, and
enal dysfunction with TEVAR. Paraplegia was not
eported in these registries (Table 4). The apparent
ifferences between registry results and clinical studies
re not surprising since the registries reported on a small
umber of patients undergoing TEVAR, and generally
ncluded only traumatic aortic injury patients with short-
erm follow-up and nonconsecutive patient inclusion. In
ddition, few registries reported on clinical outcomes
ther than short-term survival. As a result, registry data
re likely less reliable than the cumulative evidence from
linical studies of TEVAR versus open surgery.
iscussion
his meta-analysis of studies comparing TEVAR with
pen surgery for the management of descending thoracic
ortic disease provides a comprehensive aggregate analy-
is of the available evidence to date. Given that there are
o randomized trials of TEVAR versus open surgery for
escending thoracic aortic intervention, the appropriate
se of meta-analysis with metaregression represents an
mportant method to extract the best possible informa-
ion from existing data to examine the relative benefits
Odds ratio and 95% CI
alue
741
741
555
583
571
732
127
564
398
407
757
653
0.01 0.1 1 10 100
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VAR) versus open surgery. The odds ratio (OR) for death from each included
ls (width of diamonds) summarizes the effect size using the random effects
en the horizontal bars of an individual study, or the pooled diamond width,
cant, suggesting homogeneity in effect size across each study.tudy
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March 9, 2010:986–1001 TEVAR Versus Open Surgical Repair of the Descending Aortang for differences in patient characteristics inherent in
he observational trials.
Overall, existing evidence suggests that TEVAR reduces the
isk of all-cause mortality at 30 days. Survival at 1 year and
eyond did not show a definitive benefit for TEVAR com-
ared with open surgery; however, survival data after discharge
ere less commonly reported in the trials, and the trend was
onsistently in favor of TEVAR for the studies reporting
-year cumulative all-cause mortality (p  0.07), with no
ignificant heterogeneity across the trials for this outcome. At
inimum, the existing evidence shows that survival for
EVAR is not worse than for open surgery at midterm.
urther studies, preferably randomized, with adequate power
nd complete follow-up will be needed to better define
hether there are important long-term survival benefits for
EVAR over open surgery (78).
This analysis also shows that the risk of paraplegia/
araparesis is reduced for TEVAR versus open surgery.
his has important implications for the long-term func-
ionality and quality of life for patients undergoing
horacic aortic repair. Even when the definition was
imited to permanent paraplegia, TEVAR provided sig-
ificant benefit over open surgery. It is important to note
hat some trials employed protective techniques such as
outine cerebrospinal fluid drainage, whereas others did
Study name Statistics for each study
Odds Lower Upper 
ratio limit limit p-Val
TAG 99-01 0.65 0.22 1.93 0.
Matsumura 08 0.29 0.09 0.95 0.
Fairman 09 0.48 0.19 1.22 0.
0.46 0.25 0.85 0.
Akowuah 07 0.33 0.01 9.57 0.
Brandt 04 0.48 0.04 5.67 0.
Buz 08 4.73 0.22 102.05 0.
Dick 08 1.38 0.38 5.05 0.
Doss 05 2.71 0.11 69.34 0.
Glade 05 0.24 0.01 5.19 0.
Keiffer 08 4.22 1.31 13.59 0.
McPhee 07 0.57 0.03 11.85 0.
Morishita 04 0.19 0.01 5.07 0.
Najibi 02 0.16 0.01 4.37 0.
Nienaber 99 0.11 0.00 2.36 0.
Patel 08 0.62 0.18 2.20 0.
Riesenman 07 3.62 0.21 61.82 0.
Stone 06 1.29 0.47 3.55 0.
1.12 0.64 1.94 0.
0.75 0.50 1.13 0.
Single center 
Overall
Multicenter 
Figure 5 Stroke for TEVAR Versus Open Surgery
Meta-analysis comparing stroke for thoracic endovascular aortic repair (TEVAR) ver
pooled estimate of overall OR (diamonds) and 95% confidence intervals (width of
left of 1.0 favor TEVAR; effects to the right favor open surgery. When the horizont
not significantly different. The I2 for heterogeneity was not significant, suggesting hot. Despite these practice differences, there was no cetectable statistical heterogeneity across the trials for
his outcome, and confidence in this result is heightened.
Other important benefits of TEVAR include reduction
f renal dysfunction, transfusions, reoperation for bleed-
ng, cardiac complications, neurologic complications,
neumonia, respiratory complications, reduced incidence
f any complication, and shorter procedure time, and
ength of stay in intensive care unit or hospital.
Since there was generally low heterogeneity across
rials, this lends credence to the robustness of the results
cross studies. Metaregressions and subanalyses of the
esults by various characteristics, including baseline char-
cteristic differences and study design features, failed to
how material changes in the results, again lending
redence to the stability of the results across the studies.
ndoleaks and aortic graft reinterventions. There was a
aucity of information on the true incidence of endoleaks
nd most studies limited their reporting, if any, to type I and
I endoleaks since many had insufficient longitudinal
ollow-up to adequately ascertain type III and IV endoleaks.
he incidence of endoleak was 12% overall; however, this
alue should be interpreted with caution since a number of
rials did not report on endoleaks, and hence did not
ontribute to the summary estimate of incidence.
tudy strengths and limitations. This study represents a
Odds ratio and 95% CI
0.01 0.1 1 10 100
Favors TEVAR Favors OPEN
en surgery. The odds ratio (OR) for stroke from each included study is plotted. A
nds) summarizes the effect size using the random effects model. Effects to the
of an individual study, or the pooled diamond width, cross 1.0, the effect is
eneity in effect size across each study.ue
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TEVAR Versus Open Surgical Repair of the Descending Aorta March 9, 2010:986–1001nalysis of existing evidence for TEVAR versus open
urgery in the management of descending thoracic aortic
isease. Adherence to current guidelines for performing
eta-analyses of observational studies was undertaken to
nsure highest possible objectivity in analyses (11,12). Un-
ike previous systematic reviews in this area, this meta-
nalysis synthesizes all clinically relevant outcomes rather
han a few selected outcomes, performs metaregression, and
lso included all major aortic pathologies rather than focus-
ng on a single pathology only. This allows for comparisons
f the balance of clinical outcomes across all pathologies.
here possible, methods to incorporate time-to-event data
n the survival analyses were used to ensure best possible
stimates of survival at each time point (79,80).
Despite the quality methodology used in this meta-
nalysis, this analysis should be interpreted in light of the
hortcomings of the available data. The most important
Study name Statistics for each study
Odds Lower Upper 
ratio limit limit p-Value
TAG 99-01 0.183 0.058 0.581 0.004
382.0099.2420.0662.08 0 sedairtemeD
Matsumura 08   0.983 0.292 3.307 0.978
Fairman 08 0.494 0.261 0.934 0.030
0.436 0.225 0.844 0.014
Aasland 05 0.323 0.034 3.080 0.326
Akowuah 07 0.333 0.012 9.566 0.521
Andrassy 06 0.114 0.006 2.335 0.159
Brandt 04 0.476 0.040 5.671 0.557
Broux 06 0.407 0.015 10.832 0.592
Chung 08 0.063 0.003 1.151 0.062
Cook 06 0.385 0.015 9.995 0.565
Dick 08 1.360 0.185 9.986 0.762
Doss 05 0.871 0.052 14.604 0.923
Ehrlich 98 0.327 0.017 6.177 0.456
Glade 05 0.299 0.032 2.779 0.288
Keiffer 08 0.113 0.006 1.975 0.135
Kokotsakis 07  0.429 0.024 7.632 0.564
Midgely 07 0.413 0.015 11.053 0.598
Mohan 08 0.264 0.010 7.117 0.428
Morishita 04 0.189 0.007 5.073 0.321
Nienaber 99 0.168 0.007 3.902 0.266
Ott 04 0.323 0.013 7.847 0.488
Pacini 05 0.341 0.017 6.687 0.478
Patel 08 0.382 0.033 4.371 0.439
Rousseau 05  0.157 0.008 3.176 0.228
Stone 06 0.759 0.264 2.180 0.608
0.402 0.237 0.683 0.001
0.415 0.275 0.628 0.000
Single center 
Overall
Multicenter 
Figure 6 Paraplegia or Pareparesis for TEVAR Versus Open Sur
Meta-analysis comparing paraplegia/pareparesis for thoracic endovascular aortic r
from each included study is plotted. A pooled estimate of overall OR (diamonds) a
random effects model. Effects to the left of 1.0 favor TEVAR; effects to the right f
mond width, cross 1.0, the effect is not significantly different. The I2 for heterogeimitation is the absence of randomized trials comparing pEVAR versus open surgery, and the risks of systematic
ias inherent to observational studies. In some studies,
EVAR was compared with a historical control. The
istoricity of the control group increases the risk of bias
avoring TEVAR since outcomes of patients with descend-
ng thoracic aortic disease may be improving over time due
o better contemporary detection and overall management
f aortic disease. Nonetheless, in our regression analysis
y historicity of control group, the ORs did not materi-
lly change for historical versus contemporaneous con-
rols. In addition, analysis by various features of study
esign (consecutiveness of patient inclusion, retrospective
s. prospective) also failed to show material changes in
he results.
In some studies, the duration of follow-up was longer
or the open surgery group than the TEVAR group. This
ay bias the results against open surgery, since increased
Odds ratio and 95% CI
0.1 1 10
Favors TEVAR Favors OPEN
100
TEVAR) versus open surgery. The odds ratio (OR) for paraplegia/pareparesis
% confidence intervals (width of diamonds) summarizes the effect size using the
pen surgery. When the horizontal bars of an individual study, or the pooled dia-
as not significant, suggesting homogeneity in effect size across each study.0.01
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March 9, 2010:986–1001 TEVAR Versus Open Surgical Repair of the Descending Aortauring shorter follow-up. In a post-hoc sensitivity anal-
sis limited to studies with similar duration of follow-up
etween TEVAR and open surgery groups, the results for
eath at 1 year and 2 to 3 years were similar as in the
riginal analysis.
There was inconsistency across studies in the description
f criteria used to select patients for TEVAR versus alter-
ative procedures. In some studies, TEVAR was reserved
or patients unfit for open surgery, or with comorbidities
hat would place them at greater risk for complications with
pen surgery. In some studies, younger and fitter patients
ere selected for the newer procedure early in the surgeon’s
xperience. Also, in the retrospective studies, it was gener-
lly unknown how many of the patients intended to undergo
Figure 7 Metaregression for Death by Age Differences at Base
Metaregression of the effect of baseline age differences on the log odds ratio for
Each circle represents a study, telescoped by its weight in the analysis. The relati
consistent over the years (p  0.13).
Figure 8 Metaregression for Death at 30 Days by Enrollment Y
Metaregression of the effect of enrollment year on the log odds ratio for the risk o
Each circle represents a study, telescoped by its weight in the analysis. The relati
consistent over the years (p  0.45).EVAR were crossed over to open surgery due to difficult
orphology or other reasons. If these cross-over patients
ere reported in the open surgical group, there may be
light overestimation of TEVAR benefit relative to open
urgery since cross-over patients are likely to have worse
utcomes and more complications than patients who were
riginally scheduled to undergo open surgery. Nonetheless,
he total contribution of crossovers to the open group is
ikely small, and we used the more conservative random
ffects analysis to avoid overestimation of benefits.
Despite extensive efforts to systematically address the
isk of including overlapping patient populations in this
nalysis, the authors acknowledge that there may be some
emaining undetected overlap within the analysis since
k of death for thoracic endovascular aortic repair (TEVAR) versus open surgery.
was nonsignificant, suggesting that the impact of TEVAR on risk of death was
h at 30 days for thoracic endovascular aortic repair (TEVAR) versus open surgery.
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ify, particularly when authors’ and centers’ names do not
xactly match from 1 patient series to the next overlap-
ing series.
In order to maximally address the limitations inherent
n nonrandomized studies, we performed metaregression
nalyses and subgroup analyses to determine whether key
atient or study characteristics measurably affected out-
omes estimates. Although patient-level data would have
ubstantially improved the ability to evaluate confound-
rs, using study-level data for metaregression allowed for
aximal information to be derived from existing evidence
n the absence of available patient-level data. It is
ncouraging that baseline characteristics such as age and
ortic pathology were not found to significantly affect the
Figure 9 Metaregression for Stroke by Enrollment Year
Metaregression of the effect of enrollment year on the log odds ratio for the risk o
cle represents a study, telescoped by its weight in the analysis. The relationship w
tent over the years (p  0.29).
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Figure 10 Metaregression for Paraplegia by Enrollment Year
Metaregression of the effect of enrollment year on the log odds ratio for the risk o
surgery. Each circle represents a study, telescoped by its weight in the analysis. T
of paraplegia/paraparesis was consistent over the years (p  0.12).verall estimate of relative benefit of TEVAR over open
urgery for all-cause mortality, stroke, or paraplegia/
araparesis. Interestingly, since the relative benefit of
EVAR over open surgery did not differ significantly by
ear of enrollment, there was no statistically detectable
earning-curve effect for earlier trials versus later trials,
lthough, the analyses may be limited in power to detect
mall differences over time. Importantly, we should not
iscount the importance of interpreting these results in
ight of the fact that results of TEVAR and open surgery
re inextricably dependent on the skills of the surgeons
nd their teams, and it is more likely for experienced
enters to publish their results than those who are early in
he learning curve. The results of this analysis also need
o be interpreted with the knowledge that the patient
e for thoracic endovascular aortic repair (TEVAR) versus open surgery. Each cir-
nsignificant, suggesting that the impact of TEVAR on risk of stroke was consis-
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urgeon’s discretion, and the criteria for determining
atient suitability for TEVAR versus open surgery were
ot explicitly declared in many studies. This analysis does
ot enable the determination of optimal patient charac-
eristics for selecting TEVAR versus open surgery.
onclusions
n patients requiring intervention for descending thoracic
ortic disease, nonrandomized evidence shows that TEVAR
ay reduce early mortality and paraplegia compared with
onventional open surgical management. TEVAR may also
educe length of hospital stay and overall complications
ncluding neurologic, cardiac, respiratory, renal, and bleed-
ng complications, without a significant increase in the need
or reintervention during mid-term follow-up. Although it
emains an important caveat that these conclusions are
ased on observational comparative studies, the consistency
f results across aortic pathologies, baseline age groups, and
ime periods of patient recruitment increases confidence
hat the findings are robust. Nonetheless, randomized trials
re required to confirm the results of this metaregression.
ny future randomized trials should be encouraged to
dhere to the guidelines for reporting studies of TEVAR
81) and will need to address clinically important gaps in the
xisting evidence base, including whether longer-term sur-
ival, stroke risk, need for reintervention, quality of life, and
atient functionality are improved, and whether the cost-
ffectiveness warrants broader uptake of TEVAR in place of
pen surgery.
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linical Outcomes for Registry DataTable 4 Clinical Outcomes for Registry Data
n/N TEVAR, % n/N
Death, 30-day 26/332 7.9 398/2,5
Death, 1-yr 7/36 19.4 13/41
Death, 2- to 3-yr 10/36 27.8 16/41
Stroke 9/294 3.1 25/789
AMI 1/27 3.7 1/26
Renal 3/27 11.1 4/26
Ischemia, gut or limb 13/54 24.1 10/52
Overall complications 55/267 20.6 253/763
bbreviations as in Tables 2 and 3.ntario N6A 5A5, Canada. E-mail: davy.cheng@lhsc.on.ca.EFERENCES
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